“Three-Dimensional Breast Cancer Spheroids” submitted by radiotherapeutics researcher Debjani Pal is stunning. Brilliant blue dots pop from an electric sphere threaded with bright colors: greens, aqua, hot pink and red.
ORNL has entered a strategic research partnership with the United Kingdom Atomic Energy Authority, or UKAEA, to investigate how different types of materials behave under the influence of high-energy neutron sources. The $4 million project is part of UKAEA's roadmap program, which aims to produce electricity from fusion.
Three researchers at ORNL have been named ORNL Corporate Fellows in recognition of significant career accomplishments and continued leadership in their scientific fields.
ORNL and the Tennessee Valley Authority, or TVA, are joining forces to advance decarbonization technologies from discovery through deployment through a new memorandum of understanding, or MOU.
More than 50 current employees and recent retirees from ORNL received Department of Energy Secretary’s Honor Awards from Secretary Jennifer Granholm in January as part of project teams spanning the national laboratory system. The annual awards recognized 21 teams and three individuals for service and contributions to DOE’s mission and to the benefit of the nation.
ORNL's Larry Baylor and Andrew Lupini have been elected fellows of the American Physical Society.
The Department of Energy’s Office of Science has selected five Oak Ridge National Laboratory scientists for Early Career Research Program awards.
The combination of bioenergy with carbon capture and storage could cost-effectively sequester hundreds of millions of metric tons per year of carbon dioxide in the United States, making it a competitive solution for carbon management, according to a new analysis by ORNL scientists.
After its long journey to Mars beginning this summer, NASA’s Perseverance rover will be powered across the planet’s surface in part by plutonium produced at the Department of Energy’s Oak Ridge National Laboratory.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.